Targeting autophagy: do patents reveal a therapeutic potential?

Bibliography

• Lefranc F, Facchini V, Kiss R. Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist 2007;12:1395-403
   PubMed Web of Science ®Google Scholar
• Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005;23:2411-22
   PubMed Web of Science ®Google Scholar
• Lefranc F, Sadeghi N, Camby I, et al. Present and potential future issues in glioblastoma treatment. Expert Rev Anticancer Ther 2006;6:719-32
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Mey V, Nannizzi S, et al. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther 2006;5:1387-95
   PubMed Web of Science ®Google Scholar
• Diamantidis M, Tsapournas G, Kountouras J, Zavos C. New aspects of regulatory signaling pathways and novel therapies in pancreatic cancer. Curr Mol Med 2008;8:12-37
   PubMed Web of Science ®Google Scholar
• Luo ML, Shen XM, Zhang Y, et al. Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res 2006;66:11690-9
   PubMed Web of Science ®Google Scholar
• Chang JY, Zhang X, Komaki R, et al. Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 2006;64:1482-94
   PubMed Web of Science ®Google Scholar
• Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81
   PubMed Web of Science ®Google Scholar
• Camidge DR. The potential of death receptor-4 and 5-directed therapies in the treatment of lung cancer. Clin Lung Cancer 2007;8:413-9
   PubMed Web of Science ®Google Scholar
• Eberle J, Kurbanov BM, Hossini AM, et al. Overcoming apoptosis deficiency of melanoma – hope for new therapeutic approaches. Drug Resist Updat 2007;10:218-34
   PubMed Web of Science ®Google Scholar
• La Porta CA. Drug resistance in melanoma: new perspectives. Curr Med Chem 2007;14:387-91
   PubMed Web of Science ®Google Scholar
• Cuervo AM. Autophagy: many paths to the same end. Mol Cell Biochem 2004;263:55-72
   PubMed Web of Science ®Google Scholar
• Kanzawa T, Germano IM, Komata T, et al. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 2004;11:448-57
   PubMed Web of Science ®Google Scholar
• Rietschel P, Wolchok JD, Krown S, et al. Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol 2008;26:2299-304
   PubMed Web of Science ®Google Scholar
• Darkes MJM, Plosker GL, Jarvis B. Temozolomide: a review of its use in the treatment of malignant gliomas, malignant melanoma and other advanced cancers. Am J Cancer 2002;1:55-80
   Google Scholar
• Mijatovic T, Mathieu V, Gaussin JF, et al. Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers. Neoplasia 2006;8:402-12
   PubMed Web of Science ®Google Scholar
• Lefranc F, Mijatovic T, Kondo Y, et al. Targeting the alpha-1 subunit of the sodium pump to combat glioblastoma cells. Neurosurgery 2008;62:211-21
   PubMed Web of Science ®Google Scholar
• Lefranc F, Kiss R. The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas. Neoplasia 2008;10:198-206
   PubMed Web of Science ®Google Scholar
• Boland B, Nixon RA. Neuronal macroautophagy: from development to degeneration. Mol Aspects Med 2006;27:503-19
   PubMedGoogle Scholar
• Settleman J, Sharma S, McDermott U. Autophagic compound combination with EGFR tyrosine kinase inhibitor of cancer. WO2008036254; 2008
   Google Scholar
• Kim YS, Kwon MH, Lee SH, et al. Antibody specifically binding to DR5 and composition for preventing or treating cancers comprising the same. WO2008004760; 2008
   Google Scholar
• Hazlehurst LA, Dalton WS, Cress AE. HYD1 peptides as anti-cancer agents. WO2008031064; 2008
   Google Scholar
• Gorski SM, Qadir MA. Inhibition of autophagy genes in cancer chemotherapy. WO2007051316; 2007
   Google Scholar
• Osumi Y, Takao T, Noda K, Kirisako T. Complex of protein and phosphatidylethanolamine. JP2002348298; 2002
   Google Scholar
• Levine BC. Beclin and uses thereof. US6432914; 2002
   Google Scholar
• Baehrecke EH, Alva A, Leonardo MJ, Li Y. Function of autophagy genes in cell death. US2005276809; 2005
   Google Scholar
• Rubinsztein D, Sarkar S. Methods of autophagy induction in mammalian cells. WO2006079792; 2006
   Google Scholar
• Rubinsztein D, Ravikumar B, Webb J. Methods and means for treating protein conformational disorders. WO2004089369; 2004
   Google Scholar
• Rubinsztein D, Sarkar S, Williams A, et al. Modulation of autophagy by calpain inhibition. WO2007003941; 2007
   Google Scholar
• Shacka JJ, Roth KA. Prevention of neurodegeneration using macrolide antibiotics. WO2007022076; 2007
   Google Scholar
• Munz C. Methods and agents for modulating an immune response. WO2007098060; 2007
   Google Scholar
• Thompson CB, Lum J, Bauer D. Regulation of autophagy and cell survival. WO2006078774; 2006
   Google Scholar
• Poikas-Cezanne T, Nordheim A. Diagnosis and therapy of autophagy-associated diseases. WO2006048234; 2006
   Google Scholar
• Hu HM. Defective ribosomal products in blebs (Dribbles) and methods of use to stimulate an immune response. WO2007016340; 2007
   Google Scholar
• Ijichi C, Yamada N, Hatanaka T, et al. Dpp4 inhibitor and pharmaceutical application thereof. WO2006118196; 2006
   Google Scholar
• Mograbi B, Corcelle E, Barriere H, Poujeol P. CFTR as a component of an autophagy signaling pathway, applications thereof to autophagic diseases and determination of cystic fibrosis as an autophagic disease. WO2006048338; 2006
   Google Scholar
• Cham BE, Daunter B. Glycoalkaloids. WO9110743; 1991
   Google Scholar
• Lefranc F, Kiss R. Autophagy, the Trojan horse to combat glioblastomas. Neurosurg Focus 2006;20(4):E7
   PubMedGoogle Scholar